HLA-G and neoplasm: In addition, the relevance of this immunosuppressive molecule in ccRCCs has already been demonstrated [63], and, in analogy to HLA-G, there are already mAbs against this tumor immune checkpoint for anti-tumor therapies [71,72,73].